- Home
- BFS vs GHRS Comparison
BFS vs GHRS Comparison
Compare BFS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFS
- GHRS
- Stock Information
- Founded
- BFS 1993
- GHRS 2018
- Country
- BFS United States
- GHRS Ireland
- Employees
- BFS N/A
- GHRS N/A
- Industry
- BFS Real Estate Investment Trusts
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- BFS Real Estate
- GHRS Health Care
- Exchange
- BFS Nasdaq
- GHRS Nasdaq
- Market Cap
- BFS 830.6M
- GHRS 849.8M
- IPO Year
- BFS 1993
- GHRS 2021
- Fundamental
- Price
- BFS $34.51
- GHRS $12.31
- Analyst Decision
- BFS Strong Buy
- GHRS Strong Buy
- Analyst Count
- BFS 1
- GHRS 8
- Target Price
- BFS $45.50
- GHRS $30.63
- AVG Volume (30 Days)
- BFS 51.9K
- GHRS 187.6K
- Earning Date
- BFS 07-31-2025
- GHRS 05-08-2025
- Dividend Yield
- BFS 6.75%
- GHRS N/A
- EPS Growth
- BFS N/A
- GHRS N/A
- EPS
- BFS 1.47
- GHRS N/A
- Revenue
- BFS $274,011,000.00
- GHRS N/A
- Revenue This Year
- BFS $7.78
- GHRS N/A
- Revenue Next Year
- BFS $6.78
- GHRS N/A
- P/E Ratio
- BFS $23.76
- GHRS N/A
- Revenue Growth
- BFS 5.04
- GHRS N/A
- 52 Week Low
- BFS $31.25
- GHRS $6.00
- 52 Week High
- BFS $42.39
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- BFS 53.40
- GHRS 52.37
- Support Level
- BFS $33.89
- GHRS $12.43
- Resistance Level
- BFS $35.44
- GHRS $13.15
- Average True Range (ATR)
- BFS 0.74
- GHRS 0.99
- MACD
- BFS 0.02
- GHRS -0.14
- Stochastic Oscillator
- BFS 57.27
- GHRS 41.03
About BFS Saul Centers Inc.
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.